● Recruiting

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Condition: Sporadic Inclusion Body Myositis (sIBM) · Idiopathic Inflammatory Myopathies · Sponsor: Austin Neuromuscular Center

PhaseEARLY_Phase 1

Planned participants10

Who can joinAll sexes, 45 Years to 75 Years

Healthy volunteersNo

About this study

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

This description comes directly from the study's public registry record.

Talk to the study team

Yessar Hussain, MD · 5129200140 · research@austinneuromuscle.com

Emil Hussain, Manager · 5129200140 · emil@austinneuromuscle.com

Always discuss trial participation with your own doctor first.

Locations (2)

Austin Neuromuscular Center	Austin, Texas, United States	Recruiting
Austin Neuromuscular Center	Austin, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06479863